OBJECTIVES: To describe progression and resolution of uveitis-associated cystoid macular edema (uvCME) using spectral-domain optical coherence tomography and find predictive factors for successful intravitreal triamcinolone acetonide (IVTA) therapy. METHODS: Twenty-nine eyes with treatment-naive uvCME were examined before and at 5 scheduled visits within 3 months after intravitreal triamcinolone acetonide administration. Distribution, resolution, relapse, and development of uvCME were evaluated using spectral-domain optical coherence tomography to describe morphology, progression, and relapse according to a standardized reading protocol. Applying repeated measures analysis of variance, morphologic findings were evaluated as predictive factors of the treatment outcome. RESULTS: At baseline, 89.3% presented with focal CME; 65.6% had outer nuclear/Henley's layer and inner nuclear layer cysts. Following intravitreal triamcinolone acetonide administration, cysts of outer nuclear/Henley's layer diminished before those of inner nuclear layer (P = 0.0004). Small-pointed subretinal detachment (SRD) resolution synchronized with inner nuclear layer cyst extinction, whereas dome-shaped SRD resolution lagged behind (P = 0.014). Relapses of CME appeared in 71.4% of eyes with parafoveal inner nuclear layer cysts. Cysts of outer nuclear/Henley's layer were present in an additional 28.6%. None of the eyes developed SRD during CME relapse. The main effect variables "SRD" and "absence of epiretinal membrane" were associated with greater best-corrected visual acuity improvement (P = 0.05 and P = 0.047), whereas the side effect variables "CME duration", "age," and "uveitis location" had no additional effect on best-corrected visual acuity. Baseline SRD predicted a relapse-free clinical course within the observational period (P = 0.025). CONCLUSION: Different morphologic patterns in uvCME may represent different stages in uvCME progression, and initial morphologic appearance can be linked to the clinical prognosis after the treatment.
OBJECTIVES: To describe progression and resolution of uveitis-associated cystoid macular edema (uvCME) using spectral-domain optical coherence tomography and find predictive factors for successful intravitreal triamcinolone acetonide (IVTA) therapy. METHODS: Twenty-nine eyes with treatment-naive uvCME were examined before and at 5 scheduled visits within 3 months after intravitreal triamcinolone acetonide administration. Distribution, resolution, relapse, and development of uvCME were evaluated using spectral-domain optical coherence tomography to describe morphology, progression, and relapse according to a standardized reading protocol. Applying repeated measures analysis of variance, morphologic findings were evaluated as predictive factors of the treatment outcome. RESULTS: At baseline, 89.3% presented with focal CME; 65.6% had outer nuclear/Henley's layer and inner nuclear layer cysts. Following intravitreal triamcinolone acetonide administration, cysts of outer nuclear/Henley's layer diminished before those of inner nuclear layer (P = 0.0004). Small-pointed subretinal detachment (SRD) resolution synchronized with inner nuclear layer cyst extinction, whereas dome-shaped SRD resolution lagged behind (P = 0.014). Relapses of CME appeared in 71.4% of eyes with parafoveal inner nuclear layer cysts. Cysts of outer nuclear/Henley's layer were present in an additional 28.6%. None of the eyes developed SRD during CME relapse. The main effect variables "SRD" and "absence of epiretinal membrane" were associated with greater best-corrected visual acuity improvement (P = 0.05 and P = 0.047), whereas the side effect variables "CME duration", "age," and "uveitis location" had no additional effect on best-corrected visual acuity. Baseline SRD predicted a relapse-free clinical course within the observational period (P = 0.025). CONCLUSION: Different morphologic patterns in uvCME may represent different stages in uvCME progression, and initial morphologic appearance can be linked to the clinical prognosis after the treatment.
Authors: R S Grajewski; A C Boelke; W Adler; S Meyer; A Caramoy; B Kirchhof; C Cursiefen; L M Heindl Journal: Eye (Lond) Date: 2016-07-08 Impact factor: 3.775
Authors: Brian Lehpamer; Erin Moshier; Patricia Pahk; Naomi Goldberg; Jessica Ackert; James Godbold; Douglas A Jabs Journal: Am J Ophthalmol Date: 2014-01-30 Impact factor: 5.258
Authors: Debra A Goldstein; Diana Do; Glenn Noronha; Jennifer M Kissner; Sunil K Srivastava; Quan D Nguyen Journal: Transl Vis Sci Technol Date: 2016-12-14 Impact factor: 3.283
Authors: Barbara Berasategui; Alex Fonollosa; Joseba Artaraz; Ioana Ruiz-Arruza; Jose Ríos; Jessica Matas; Victor Llorenç; David Diaz-Valle; Marina Sastre-Ibañez; Pedro Arriola-Villalobos; Alfredo Adan Journal: BMC Ophthalmol Date: 2018-07-20 Impact factor: 2.209
Authors: Jessica Matas; Victor Llorenç; Alex Fonollosa; Cristina Esquinas; David Diaz-Valle; Barbara Berasategui; Marina Mesquida; Joseba Artaraz; Jose Rios; Alfredo Adan Journal: PLoS One Date: 2019-01-24 Impact factor: 3.240